Main content area

Therapeutic administration of enrofloxacin in mice does not select for fluoroquinolone resistance in Campylobacter jejuni

Inglis, G. Douglas, Zaytsoff, Sarah J.M., Selinger, L. Brent, Taboada, Eduardo N., Uwiera, Richard R.E.
Canadian journal of microbiology 2018 v.64 no.10 pp. 681-694
Bacteroidetes, Campylobacter jejuni, Enterobacteriaceae, Firmicutes, animal models, antibiotics, bacteria, beef cattle, bioactive properties, bovine respiratory disease, ciprofloxacin, digesta, enrofloxacin, feces, intestines, mice, minimum inhibitory concentration, risk, subcutaneous injection, therapeutics, Canada
Enrofloxacin is registered for therapeutic use in beef cattle to treat bovine respiratory disease in Canada. A murine model was used to experimentally examine the impact of therapeutic administration of enrofloxacin on fluoroquinolone resistance development in Campylobacter jejuni. Administration of enrofloxacin to mice via subcutaneous injection or per os routes resulted in equivalent levels of bioactive enrofloxacin within the intestine, but bioactivity was short-lived (<48 h after cessation). Enrofloxacin administration did not affect densities of total bacteria, Firmicutes, or Bacteroidetes in digesta and had modest impacts on densities of Enterobacteriaceae. All mice inoculated with C. jejuni NCTC 11168 became persistently colonized by the bacterium. Enrofloxacin reduced C. jejuni cell densities within the cecal and colonic digesta for all treatments, and densities shed in feces as a function of antibiotic duration. None of the C. jejuni isolates recovered from mice after administration of enrofloxacin (n = 260) developed resistance to ciprofloxacin regardless of method or duration of administration. Furthermore, only modest shifts in the minimum inhibitory concentration of the isolates by treatment were noted. The study findings indicate that the risk posed by short-term subcutaneous administration of enrofloxacin for the development of fluoroquinolone resistance in mammals is low.